Semaglutide eligibility for weight loss requires a BMI of 30 or higher — or a BMI of 27–29.9 plus at least one qualifying health condition such as high blood pressure, prediabetes, or sleep apnea. Tirzepatide (Zepbound) follows the same thresholds. Most applicants discover their semaglutide eligibility status through a brief online intake completed in under 15 minutes with no in-person visit required.
By Alexandru Vieru | Independently researched | Published August 2026. Semaglutide eligibility criteria verified against FDA prescribing information for Wegovy and Zepbound.
Semaglutide Eligibility: The Two BMI Thresholds
The FDA-approved eligibility criteria for Wegovy (brand-name semaglutide) are also applied by telehealth clinics prescribing compounded semaglutide. There are two qualifying paths, and most applicants fall under at least one:
| Path | BMI threshold | Additional requirement |
|---|---|---|
| Primary obesity threshold | BMI ≥ 30 | None — BMI alone qualifies you |
| Overweight + comorbidity | BMI ≥ 27 | At least one qualifying health condition (see below) |
BMI ≥ 30 (obesity): approximately 42% of US adults fall here. Semaglutide eligibility on this path is automatic — no secondary condition is needed.
BMI 27–29.9 (overweight): you meet semaglutide eligibility here if a weight-related health condition is present. This adds roughly another 31% of US adults to the eligible pool.
Combined, close to 7 in 10 American adults satisfy basic semaglutide eligibility criteria — making GLP-1 weight-loss medication one of the most broadly available prescription options in 2026.
To calculate your BMI, divide your weight in pounds by your height in inches squared, then multiply by 703. The CDC BMI calculator does this instantly. Online clinics compute it automatically from your weight and height at intake.
Age requirement: all current FDA-approved GLP-1 weight management indications are for adults 18 and older. Most telehealth clinics prescribe compounded semaglutide to adults only, regardless of the adolescent Wegovy approval issued in 2023.
The BMI ≥ 27 Path: Which Conditions Qualify?
If your BMI is between 27 and 29.9, your semaglutide eligibility depends on having at least one of these documented weight-related comorbidities:
| Qualifying comorbidity | Clinical notes |
|---|---|
| Hypertension (high blood pressure) | Most common qualifier; even informal history ("my doctor told me my BP runs high") is accepted at most telehealth clinics for compounded GLP-1 |
| Prediabetes | HbA1c 5.7–6.4% meets the threshold; a prior diagnosis without current labs is often sufficient |
| Type 2 diabetes | Strong qualifier; HbA1c ≥ 6.5% |
| Dyslipidemia | Elevated LDL or triglycerides; a prior lab result or physician diagnosis |
| Obstructive sleep apnea (OSA) | A formal diagnosis, even untreated; tirzepatide (Zepbound) holds a specific FDA approval for OSA since 2024 |
| PCOS (polycystic ovary syndrome) | Broadly accepted across GLP-1 telehealth platforms |
| Cardiovascular disease (CVD) | Prior MI, stroke, or peripheral artery disease; also the basis of Wegovy's cardiovascular outcome indication |
| Fatty liver disease (NAFLD/MASH) | Increasingly recognized by prescribers in 2026 |
Documentation at telehealth clinics: clinics prescribing compounded semaglutide typically accept self-reported comorbidity history via the online intake form. Formal labs or physician notes are rarely required upfront. Insurance prior authorization for brand-name Wegovy is different — carriers often require documented prior treatment attempts and clinical records.
Practical takeaway: if your BMI is 28 and your doctor has ever mentioned your blood pressure is elevated, your semaglutide eligibility is almost certain. The online intake at reputable clinics is free, takes 10–15 minutes, and confirms eligibility the same day.
Gala Health — our #1 overall pick (8.3/10) at $149/month — accepts patients via both BMI paths with a 24-hour async clinician review.
Who Does Not Qualify: Absolute and Relative Disqualifiers
Confirming semaglutide eligibility on BMI is necessary but not sufficient. Prescribers also screen for contraindications.
Absolute contraindications (will not prescribe):
- Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 receptor agonists carry an FDA boxed warning for thyroid C-cell tumors based on rodent data; a personal or first-degree family history of MTC is a firm disqualifier
- Multiple Endocrine Neoplasia type 2 (MEN 2) — same thyroid tumor risk profile as MTC
- Active pancreatitis — GLP-1 medications slow gastric motility and are contraindicated during an active episode
Relative contraindications (evaluated individually):
- History of pancreatitis — a single resolved episode is often manageable with close monitoring; multiple episodes may prevent prescribing
- Severe renal impairment (eGFR < 30 mL/min) — dose adjustment may be needed; very severe cases may require alternative approaches
- Gastroparesis — GLP-1 agonists slow gastric emptying; pre-existing gastroparesis can worsen under treatment
- Active or recent eating disorder history — anorexia nervosa or bulimia nervosa typically triggers a referral to a specialist before GLP-1 is started
Pregnancy and breastfeeding: GLP-1 medications should be stopped at least two months before attempting conception. Active pregnancy is a contraindication; breastfeeding safety has not been established for this drug class.
Medications that may complicate prescribing:
- Insulin or sulfonylureas in Type 2 diabetes — hypoglycemia risk is real when adding GLP-1; physician-supervised dose reduction of the existing medication is standard
- Oral drugs with narrow absorption windows — compounded oral semaglutide (sublingual) requires timing coordination with other medications taken on an empty stomach
What the Semaglutide Eligibility Intake Looks Like
Once you've confirmed your theoretical semaglutide eligibility, the online intake process at a reputable telehealth clinic follows these steps:
1. Online questionnaire (10–15 minutes). You provide weight, height, health conditions, current medications, and answer contraindication screening questions. No video call is required at most GLP-1 clinics.
2. Async clinician review (4–24 hours). A US board-certified physician or nurse practitioner reviews your submission. At leading clinics, decisions come back within 4–8 hours on business days. The clinician may send a follow-up question through the patient portal.
3. Prescription issued. Once approved, the prescription routes electronically to the clinic's partner 503A compounding pharmacy or to a retail pharmacy for brand-name GLP-1.
4. Medication shipped (2–5 business days). Compounded semaglutide ships temperature-controlled — most arrive via overnight or 2-day air from a US-licensed compounding pharmacy.
5. Ongoing oversight. Monthly or quarterly check-ins for dose titration, side effect monitoring, and weight tracking. Most clinics offer async messaging access to the clinical team between visits.
The full timeline from starting your intake to holding your first injection kit in hand is typically 3–7 calendar days at top-tier clinics.
Wellorithm is the only clinic in our ranking offering brand-name Wegovy, Ozempic, Mounjaro, and Zepbound alongside compounded semaglutide and tirzepatide — a useful starting point if you want to explore whether insurance may cover brand-name while keeping compounded as a backup.
Semaglutide vs. Tirzepatide: Does Eligibility Differ?
The BMI thresholds for semaglutide eligibility (≥ 30 or ≥ 27 + comorbidity) apply equally to tirzepatide (Zepbound, Mounjaro). Both FDA-approved brand-name medications share the same weight management indication criteria. The meaningful clinical differences are in outcome and cost:
| Medication | Mechanism | Avg. weight loss | Starting price (compounded) |
|---|---|---|---|
| Compounded semaglutide | GLP-1 agonist | ~15% body weight | $99–$149/mo |
| Wegovy (brand semaglutide) | GLP-1 agonist | ~15% body weight (STEP-1 trial) | ~$899/mo cash |
| Compounded tirzepatide | GLP-1 + GIP dual agonist | ~22.5% body weight | $179–$249/mo |
| Zepbound (brand tirzepatide) | GLP-1 + GIP dual agonist | ~22.5% body weight (SURMOUNT-1) | $399–$549/mo (Lilly Direct) |
The STEP-1 trial, published in the New England Journal of Medicine (2021), established a 14.9% mean body weight reduction with semaglutide 2.4 mg over 68 weeks versus 2.4% on placebo. SURMOUNT-1 for tirzepatide showed 22.5% at 72 weeks, a statistically and clinically significant difference.
Which to choose: if maximum average weight loss is the priority, tirzepatide has a meaningful trial advantage. If cost is the priority, compounded semaglutide at $99–$149/month represents a significantly lower entry point. For a detailed breakdown by patient profile, see our semaglutide vs. tirzepatide comparison.
How Much Does GLP-1 Cost Once You Confirm Eligibility?
Semaglutide eligibility is only part of the equation — cost determines which program fits your situation. Our full GLP-1 cost guide covers this in detail. Key price tiers in August 2026:
Compounded GLP-1 (no insurance required, no prior auth):
| Price tier | Clinic | Monthly cost | Lock-in? |
|---|---|---|---|
| Budget (12-mo plan) | HealthRX | $99/mo | Yes — 12-month commitment |
| Budget (no lock-in) | Oak | $133/mo | No — month-to-month |
| Mid-range | Yucca Health | $146/mo | 6-month plan |
| Mid-range | Wellorithm | $147/mo | Flexible |
| Mid-range | Gala Health | $149/mo | Flexible |
Brand-name GLP-1:
- Wegovy (semaglutide): ~$899+/month at retail; effectively $0–$100/month for commercially insured patients who qualify for the Novo Nordisk savings card
- Zepbound (tirzepatide): $399–$549/month through Lilly Direct's vial program; pen format at retail runs $1,000+/month
Insurance: most large commercial carriers (UnitedHealthcare, Aetna, Cigna, BCBS) cover Wegovy for patients meeting semaglutide eligibility thresholds with prior authorization. Medicare Part D covers Wegovy only for patients with established cardiovascular disease. For the full prior auth process, see our GLP-1 insurance coverage guide.
Regulatory note: compounded semaglutide is not FDA-approved. It is prescribed by a licensed US clinician and prepared by a 503A compounding pharmacy under state and federal law. It is legally available in 2026. For current regulatory status, see our guide: Is Compounded Semaglutide Still Legal in 2026?
Best Online GLP-1 Clinics by Eligibility Profile
All five clinics below accept patients with BMI ≥ 30 or BMI ≥ 27 + comorbidity, across all 50 states, with asynchronous intake. Scores are based on our five-criteria rubric; commission does not affect ranking.
| Your profile | Best pick | Why |
|---|---|---|
| BMI ≥ 30, want brand-name access | Wellorithm ($147/mo) | Only clinic in our ranking with Wegovy + Zepbound + compounded options |
| BMI ≥ 30, best overall value | Gala Health ($149/mo) | Best Overall 8.3/10; microdosing tier; 24-hour review |
| BMI ≥ 27 + comorbidity, strong clinical oversight | Yucca Health ($146/mo) | Free UPS 2-Day Air; 4.6/5 Trustpilot (1,000+ reviews) |
| Budget-first, any qualifying BMI | HealthRX ($99/mo, 12-mo plan) | Cheapest injectable in our ranking; LegitScript 503A; 30-day money-back |
| No lock-in commitment | Oak ($133/mo) | Month-to-month, no annual contract; LegitScript certified |
For a deeper look at the safety signals to verify before signing up, see our GLP-1 Buyer Safety Hub.
Commission is earned on qualifying purchases through links on this page at no additional cost to you. See affiliate disclosure and editorial policy.
Frequently Asked Questions
What are the semaglutide eligibility requirements in 2026? Semaglutide eligibility requires a BMI ≥ 30 (obesity), or a BMI ≥ 27 (overweight) with at least one qualifying comorbidity — hypertension, prediabetes, type 2 diabetes, sleep apnea, dyslipidemia, CVD, or PCOS. A licensed US clinician confirms semaglutide eligibility through an online intake form; no in-person visit is required.
Can I get semaglutide with a BMI of 27? Yes — semaglutide eligibility at BMI 27–29.9 is possible if you have a qualifying comorbidity. Common qualifiers include elevated blood pressure, prediabetes (HbA1c ≥ 5.7%), high cholesterol, PCOS, and sleep apnea. Telehealth clinics prescribing compounded semaglutide generally accept self-reported history.
What disqualifies you from semaglutide? Absolute disqualifiers are a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, and active pancreatitis. Pregnancy and breastfeeding are contraindications. Gastroparesis and severe renal impairment are evaluated case by case.
Is prior treatment failure required to confirm semaglutide eligibility? No — telehealth clinics prescribing compounded semaglutide do not require documented prior diet or exercise failures. Some insurance prior authorization processes for brand-name Wegovy may impose this requirement, but the clinics themselves do not.
How quickly can I confirm semaglutide eligibility online? The intake questionnaire takes 10–15 minutes. Clinician review is completed within 4–24 hours. If approved, the prescription is issued the same day and medication typically arrives within 2–5 business days.
Top Picks
| Clinic | Score | Starting price | Best for |
|---|---|---|---|
| Wellorithm | 8.3/10 | $147/mo | Brand-name + compounded, maximum options |
| Gala Health | 8.3/10 | $149/mo | Best Overall, microdosing tier |
| Yucca Health | 7.8/10 | $146/mo | Clinical oversight + fast free shipping |
| Oak | 7.7/10 | $133/mo | No lock-in, month-to-month |
| HealthRX | 7.8/10 | $99/mo* | Lowest price — 12-month plan required |
HealthRX $99/mo requires a 12-month upfront commitment; steps up to $133/mo on a 3-month plan.
Related Reading
- GLP-1 Weight Loss Cost in 2026: All-In Prices Verified
- Semaglutide vs. Tirzepatide: Which Produces Better Results?
- Compounded vs. Brand Semaglutide: Cost, Safety & How to Choose
- Is Compounded Semaglutide Still Legal in 2026?
- Zepbound Insurance Coverage in 2026: Which Plans Pay?
- Cheapest GLP-1 Clinics Online in 2026 (Verified)
- GLP-1 Buyer Safety: How to Vet an Online Clinic
- Compare GLP-1 Clinics Side-by-Side
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists require a valid prescription from a licensed US clinician. Individual semaglutide eligibility is determined by a qualified healthcare provider based on your complete clinical profile. Compounded semaglutide is not FDA-approved. Consult your physician before starting any weight-loss medication.
Affiliate disclosure: MyGLP1 Guides earns referral commission on qualifying purchases made through links on this page. This does not influence our scores or rankings. See affiliate disclosure and editorial policy.
